co-amoxiclav


Also found in: Dictionary, Thesaurus, Wikipedia.

co-amoxiclav

(kō-ă-moks'i-klav),
The antibiotic mixture of amoxicillin and clavulanic acid, chiefly U.K. usage.
References in periodicals archive ?
coli isolates was also high (79%), they were surprisingly sensitive to all other classes of antimicrobials (4%, 9% and 8% for co-amoxiclav, ciprofloxacin and cefotaxime, respectively).
In the co-amoxiclav and co-amoxiclav plus erythromycin groups no significant difference in the primary outcome--and few in secondary outcomes--were seen compared with placebo.
Analysis of all uncomplicated UTIs (N=28) showed resistance to co-amoxiclav in only 4% (N=1).
She was given a course of oral co-amoxiclav 625 mg 3x daily.
This is of major public health importance, especially concerning Escherichia coli, a commonly isolated uropathogen, and other Enterobacteriaceae which have become less susceptible to widely used antibiotics such as ampicillin, amoxicillin, co-amoxiclav and co-trimoxazole.
During this period a 3-week course of oral co-amoxiclav (375 mg, every 8 h) was prescribed.
pneumoniae (N=503) (N=548) Antibiotic Overall (range) Overall (range) Ampicillin 82 (65-90) 100 (-) Co-amoxiclav 39 (0-57) 62 (31-73) Cefuroxime 18 (0-33) 62 (31-72) Ceftriaxone/cefotaxime 7 (0-15) 57 (43-66) Cefepime 5 (0-14) 54 (50-64) Piperacillin-tazobactam 9 (0-23) 49 (26-67) Ciprofloxacin 16 (0-36) 39 (18-64) Levofloxacin 16 (0-36) 39 (28-64) Gentamicin 14 (0-32) 31 (0-43) Amikacin 6 (0-15) 25 (8-50) Ertapenem 2 (0-8) 2 (0-8) Imipenem 1 (0-6) 1 (0-1) Meropenem 1 (0- 6) 1 (0-1) % ESBL production 5 (0-11) 50 (33-59) Enterobacter spp.
Antimicrobial susceptibility testing by disc diffusion showed the organism to be resistant to colistin, ampicillin, cephalexin, gentamicin, and ciprofloxacin and susceptible to co-amoxiclav, tetracycline, cefotaxime, ceftriaxone, ceftazidime, piperacillin, and meropenem.
Co-amoxiclav was prescribed for possible aspiration pneumonia, and he was maintained on a diazepam infusion for the convulsions.
and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
Of the beta-lactam/beta-lactamase inhibitor combinations, piperacillin-tazobactam was the most active, with 89% susceptible to this agent, while susceptibility to co-amoxiclav was 63%.
Klebsiella organisms showed a high degree of multidrug resistance: 34% were resistant to co-amoxiclav or ampicillin+sulbactam, 33% to cefuroxime, and 21% to both ceftazidime and gentamicin.